Dynorphin‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy

Focal epilepsy represents one of the most common chronic CNS diseases. The high incidence of drug resistance, devastating comorbidities, and insufficient responsiveness to surgery pose unmet medical challenges. In the quest of novel, disease‐modifying treatment strategies of neuropeptides represent...

Descripción completa

Detalles Bibliográficos
Autores principales: Agostinho, Alexandra S, Mietzsch, Mario, Zangrandi, Luca, Kmiec, Iwona, Mutti, Anna, Kraus, Larissa, Fidzinski, Pawel, Schneider, Ulf C, Holtkamp, Martin, Heilbronn, Regine, Schwarzer, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783645/
https://www.ncbi.nlm.nih.gov/pubmed/31486590
http://dx.doi.org/10.15252/emmm.201809963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783645/
https://www.ncbi.nlm.nih.gov/pubmed/31486590
http://dx.doi.org/10.15252/emmm.201809963

Ejemplares similares